Title: A phase 2a, Randomized, Controlled, Observer Blind, Age de-escalation, Multicenter, multinational study of the safety, reactogenecity, and Immunogenicity of the NVGH Glycoconjugate Vaccine against S.Typhi in Adults, Children, Older Infants and Infants

Period: 8 months

Sponsor: Novartis Vaccines Institute for Global Health

Investigator/s: Dr Ashish Bavdekar

Study population/ Sample size: Vadu sample size -40

Outcome/Findings: Awaited

Feedback/Dissemination of results: Awaited

Contact Us
eg. (Mark Calcara)
eg. (yourname@domain.com)
Reach Us
BilerChildrenLeg og SpilAutobranchen